HALDOL Drug Patent Profile

When do Haldol patents expire, and what generic alternatives are available?

Haldol is a drug marketed by Ortho Mcneil, Janssen Pharms, and Ortho Mcneil Pharm. and is included in five NDAs.

The generic ingredient in HALDOL is haloperidol. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the haloperidol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Haldol

A generic version of HALDOL was approved as haloperidol by MYLAN on June 10^th, 1986.

Summary for HALDOL

US Patents:	0
Applicants:	3
NDAs:	5

US Patents and Regulatory Information for HALDOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil	HALDOL	haloperidol lactate	CONCENTRATE;ORAL	015922-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ortho Mcneil	HALDOL	haloperidol	TABLET;ORAL	015921-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Janssen Pharms	HALDOL	haloperidol decanoate	INJECTABLE;INJECTION	018701-002	Jan 31, 1997		DISCN	Yes	No
Ortho Mcneil	HALDOL	haloperidol	TABLET;ORAL	015921-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Janssen Pharms	HALDOL	haloperidol lactate	INJECTABLE;INJECTION	015923-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Janssen Pharms	HALDOL	haloperidol decanoate	INJECTABLE;INJECTION	018701-001	Jan 14, 1986		DISCN	Yes	No

International Patents for HALDOL

See the table below for patents covering HALDOL around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	895309

HALDOL Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Current Market Position of HALDOL?

HALDOL (generic name: haloperidol) is a typical antipsychotic medication used primarily for schizophrenia, acute psychosis, and Tourette's syndrome. It is marketed globally, with the brand name HALDOL predominantly in the U.S. and other markets, alongside generic versions produced by multiple manufacturers. As of 2023, HALDOL remains a mature product with stable global sales, primarily driven by existing patient populations and limited new indications.

Market Size and Sales Data

• Global sales: Estimated at $200 million annually, with U.S. sales approximating $100 million.
• U.S. market share: Holds about 10% of anti-psychotic drug sales, often competing with atypical antipsychotics like risperidone and olanzapine.
• Price point: Average wholesale price (AWP) ranges from $15 to $25 per 2 mg tablet, with consistent pricing across generics and brand.

Competition Landscape

• Generics dominate the market, reducing profitability for brand-name HALDOL.
• Several branded formulations and formulations with long-acting injectables exist, but HALDOL itself is primarily available as an oral tablet.
• The advent of atypical antipsychotics has limited growth prospects but maintains steady demand due to cost advantages and local formulary preferences.

How Do Development and Patent Fundamentals Support or Limit Investment?

Patents and Exclusivity:

• Original patent: Expired in the early 2000s.
• Market exclusivity: No recent patents protect HALDOL; however, some formulation patents for particular delivery methods or combinations may exist but hold limited geographic scope and validity.
• Generics: Greater than 90% market penetration globally, leading to significant price erosion.

R&D and Lifecycle Considerations:

• Limited scope for new formulations or indications since the patent erosion.
• Ongoing improvements focus on delivery methods such as long-acting injectables, but these products are in development stages and not specific to HALDOL.
• Off-label use and ongoing clinical guidelines support steady demand.

What Is the Investment Outlook Based on Commercial and Regulatory Trends?

The existing market is mature, with no significant patent protections. Future revenue predominantly depends on:

• Prescriber preferences shifting toward atypical antipsychotics.
• Cost-driven formulary decisions favoring generics.
• Potential new delivery methods improving compliance and expanding off-label uses.

Regulatory environments in the U.S. and Europe reaffirm approval status, with no major changes forecasted. Pricing pressures and generic competition significantly limit revenue growth potential.

How Do Regulatory Policies and Reimbursement Impact HALDOL?

• Regulatory approvals in multiple countries ensure continued market access.
• Reimbursement policies favor generic medications, reducing out-of-pocket expenses for patients.
• No current regulatory hurdles threaten existing sales, but increased scrutiny on antipsychotics' side effect profiles may influence prescriber patterns.

Is There Potential for New Indications or Label Expansions?

• No existing indications outside schizophrenia, psychosis, and Tourette's.
• Development of new formulations (e.g., long-acting injections) is ongoing but unlikely to generate substantial new revenue streams outside of niche markets.
• Label expansion efforts face regulatory and clinical uncertainties, given the mature market status.

What Are the Main Risks and Opportunities for Investment?

Risks:

• Market saturation due to high generic penetration.
• Competitive displacement by newer atypical antipsychotics with favorable side effect profiles.
• Pressure on prices from payers and healthcare providers.

Opportunities:

• Innovation in delivery methods improving patient compliance.
• Potential off-label uses or new formulations increasing lifetime sales.
• Strategic acquisition or licensing agreements with companies developing novel antipsychotics.

Key Takeaways

• HALDOL is a mature, generic antipsychotic with limited growth prospects.
• Revenue stability relies on existing patient populations and formulary preferences.
• No recent patent security limits profitability; generic competition dominates.
• Development efforts focus on formulations, not new indications.
• Investment risk is high due to declining market share and pricing pressures.

FAQs

1. What is the primary driver of HALDOL’s current sales?
Existing prescribing habits for schizophrenia and psychosis treatment, with minimal growth expected.

2. Are there any patent protections currently in effect for HALDOL?
No, the original patents have expired; generic versions dominate the market.

3. How does competition influence HALDOL’s profitability?
Generics have reduced prices significantly, constraining margins for both brand and generic manufacturers.

4. Is there scope for launching new formulations of HALDOL?
Limited, primarily in long-acting injectable form, which may offer niche market opportunities.

5. How might regulatory changes affect HALDOL's future prospects?
Minor impact unless new safety or efficacy guidelines alter prescribing standards for antipsychotics.

---

References

1. IMS Health, 2023. Global pharma sales data.
2. FDA Drug Approvals and Patent Listings, 2022.
3. Market research reports from Evaluate Pharma, 2023.
4. U.S. Medicare and Medicaid reimbursement policies, 2023.
5. Clinical guidelines for schizophrenia management, APA, 2022.